Guardion Health Sciences, Inc. Announces Pricing of Initial Public Offering
06 April 2019 - 3:49AM
Business Wire
Guardion Health Sciences Inc. (“Guardion”) (Nasdaq:GHSI), an
ocular health sciences and technologies company that develops,
formulates and distributes condition-specific medical foods and
testing technologies supported by evidence-based protocols, today
announced the pricing of its initial public offering of 1,250,000
shares of its common stock at a public offering price of $4.00 per
share for total gross proceeds of $5.0 million, before deducting
underwriting discounts and commissions and other offering costs and
expenses payable by Guardion. In addition, Guardion has granted the
underwriters a 45-day option to purchase up to 187,500 additional
shares of common stock at the public offering price, less
underwriting discounts and commissions, to cover over-allotments,
if any. All of the shares are being offered by Guardion. The shares
are expected to begin trading on the Nasdaq Capital Market on
Friday, April 5, 2019, under the symbol “GHSI.”
WallachBeth Capital, LLC is acting as the lead manager for the
IPO and WestPark Capital, Inc. is acting as co-manager.
A registration statement relating to the shares of common stock
being sold in this offering was declared effective by the
Securities and Exchange Commission (the “SEC”) on April 4, 2019.
The offering is being made only by means of a prospectus. This
press release shall not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there
be any sale of, these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Guardion Health Sciences, Inc.
Guardion is an ocular health sciences company that develops,
formulates and distributes condition-specific medical foods
supported by evidence-based protocols, with an initial medical food
product that addresses a depleted macular protective pigment, a
known risk factor for age-related macular degeneration (“AMD”), and
a significant component of functional vision performance. Guardion
Health Sciences, Inc. has also developed a proprietary medical
device, the MapcatSF®, which accurately measures the macular
pigment density, therefore providing the only two-pronged
evidence-based protocol for the treatment of a depleted macular
protective pigment.
About VectorVision®
VectorVision® specializes in the standardization of contrast
sensitivity, glare sensitivity, low contrast acuity, and ETDRS
acuity vision testing. Its patented standardization system provides
the practitioner or researcher the ability to delineate very small
changes in visual capability, either as compared to the population
or from visit to visit. VectorVision®’s CSV-1000 device is
considered the standard of care for clinical trials. VectorVision®
is a wholly-owned subsidiary of Guardion.
About WallachBeth Capital, LLC
WallachBeth Capital offers a robust range of capital markets and
investment banking services to the healthcare community, connecting
corporate clients with leading institutions, creating value for
both issuers and investors. The firm is a leading provider of
institutional execution services, offering clients a full spectrum
of solutions to help them navigate increasingly complex markets.
WallachBeth's expertise includes ETF, equity and derivative
trading. Operating on a fully disclosed, agency-only basis, the
firm is committed to facilitating all client needs with
transparency and integrity. The firm's website is located
at www.wallachbeth.com.
About WestPark Capital
WestPark Capital is a full-service investment bank focused on
emerging growth sectors such as healthcare, software, technology,
biotechnology, financial services, manufacturing, consumer
products, media and telecom industries, among other categories.
WestPark Capital provides a comprehensive range of corporate
finance services, including initial public offerings, follow-on
offerings, private placements, SIPOs and corporate finance advisory
services. Additional information about WestPark Capital is
available at www.wpcapital.com or
at info@wpcapital.com.
A registration statement relating to the shares of common stock
being sold in this offering was declared effective by the
Securities and Exchange Commission (the “SEC”) on April 4, 2019.
The offering is being made only by means of a prospectus. Copies of
the final prospectus may be obtained on the SEC’s website,
www.sec.gov, or by contacting WallachBeth Capital, LLC, Attention:
Capital Markets, Harborside Financial Center Plaza 5, 185 Hudson
Street, Ste 1410, Jersey City NJ 07311, by telephone at
646-998-7606, or by email at cap-mkts@wallachbeth.com.
Forward-Looking Statement Disclaimer
With the exception of the historical information contained in
this news release, the matters described herein may contain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements
involve unknown risks and uncertainties that may individually or
materially impact the matters discussed herein for a variety of
reasons that are outside the control of the Company, including, but
not limited to, the Company’s ability to raise sufficient financing
to implement its business plan and its ability to successfully
develop and commercialize its proprietary products and
technologies. Readers are cautioned not to place undue reliance on
these forward-looking statements, as actual results could differ
materially from those described in the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company’s registration statement filed with the SEC,
which is available at the SEC’s website (www.sec.gov). The Company
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190405005377/en/
Company Contact:Michael FavishChief Executive OfficerTelephone:
(858) 605-9055 x 201E-mail: mfavish@guardionhealth.com
Investor Relations Contact:Matthew AbenantePorter, LeVay &
RoseTelephone: (212) 564-4700E-mail: matthew@plrinvest.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Apr 2024 to May 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From May 2023 to May 2024